Reddistatin, 40 mg 30 pcs

Pharmacotherapeutic group:

Hypolipidemic drug – HMG-CoA reductase inhibitor

CodeATX: C10AA07

Pharmacological properties

Mechanism of action

Rosuvastatin is a selective competitive inhibitor of HMG-CoA reductase, the enzyme that converts Z-hydroxy-3-methylglutaryl coenzyme A to mevalonic acid, a precursor of cholesterol.

Rosuvastatin increases the number of “hepatic” low-density lipoprotein (LDL) receptors on the cell surface, increasing LDL capture and catabolism, which in turn leads to inhibition of very low-density lipoprotein (VLDL) synthesis, thereby reducing total LDL and VLDL.

Pharmacodynamics

Rosuvastatin reduces elevated LDL cholesterol (XC-LDL), total cholesterol and triglycerides (TG), increases concentrations of high-density lipoprotein cholesterol (HDL-C) and decreases concentrations of apolipoprotein B (ApoB), non-HDL-C, XC-LDL, TG-LDL, and increases apolipoprotein A-I (ApoA-I) concentrations, see Table 1, decreases the ratio of LDL-C/HC-LDL, total CH/LC-LDL and non-LDL-C/HC-LDL and the apoB/ApoA-I ratio.

Therapeutic effect develops within one week after the start of therapy with the drug, after 2 weeks of treatment it reaches 90% of the maximum possible effect.

The maximum therapeutic effect is usually reached by the 4th week of therapy and is maintained with continued regular use of the drug.

Table 1. Dose-dependent effect in patients with primary hypercholesterolemia (type IIa and IIb according to Fredrickson). Mean adjusted percentage change from baseline.

Clinical efficacy

Rosuvastatin is effective in adult patients with hypercholesterolemia with or without symptoms of hypertriglyceridemia, regardless of their race, sex, or age, including patients with diabetes and familial hypercholesterolemia.

In 80% of patients with hypercholesterolemia of type HA and IB according to Fredrickson (mean baseline concentration of XC-LDL about 4.8 mmol/L) with the use of the drug in dose of 10 mg the concentration of XC-LDL reaches values less than 3 mmol/L.

In patients with heterozygous familial hypercholesterolemia who received rosuvastatin in doses from 20 to 80 mg, positive dynamics of lipid profile parameters were observed (study with 435 patients). After titration to a daily dose of 40 mg (12 weeks of therapy) there is a 53% decrease in LDL-C concentration. In 33% of patients a concentration of less than 3 mmol/l of LDL-C was achieved.

In patients with homozygous familial hypercholesterolemia who took rosuvastatin in doses of 20 and 40 mg, the average decrease in concentration of LDL-C is 22%.

In patients with hypertriglyceridemia with an initial TG concentration of 273 to 817 mg/dL who took rosuvastatin at doses of 5 mg to 40 mg once daily for six weeks, plasma TG concentrations were significantly reduced.

Additive effect is observed in combination with fenofibrate for TG content and with nicotinic acid in lipid-lowering doses for HDL-C content (see also section “Special indications”).

. In patients with low risk of coronary heart disease (CHD) (Framingham Scale risk less than 10% over 10 years), with a mean LDL-C concentration of 4.0 mmol/L (154.5 mg/dL) and subclinical atherosclerosis, as assessed by carotid intima-media complex thickness-TCIM, rosuvastatin at a dose of 40 mg/day significantly slowed the rate of progression of maximum TCIM for 12 carotid segments compared with placebo with a difference of -0.0145 mm/yr (95% confidence interval (CI): -0.0196 to -0.0093; p < 0.001). The dose of 40 mg should only be administered to patients with significant hypercholesterolemia and high risk of cardiovascular disease (CVD).

The results of a study on the use of HMG-CoA reductase inhibitors (statins) for primary prevention showed that rosuvastatin significantly reduced the risk of cardiovascular complications with a relative risk reduction of 44%. Efficacy of therapy was noted after 6 months of using the drug.

There was a statistically significant reduction of 48% in the combined criterion including cardiovascular mortality, stroke and myocardial infarction, a 54% reduction in the occurrence of fatal or nonfatal myocardial infarction, and a 48% reduction in fatal or nonfatal stroke. Overall mortality was reduced by 20% in the rosuvastatin group.

Pharmacokinetics

Absorption and distribution

The maximum plasma concentration of rosuvastatin is reached approximately 5 hours after oral administration. Absolute bioavailability is approximately 20%.

Rosuvastatin is metabolized primarily by the liver, which is the main site of cholesterol synthesis and metabolism of LDL-C. The volume of distribution of rosuvastatin is approximately 134 liters. About 90% of rosuvastatin is bound to plasma proteins, mainly to albumin.

Metabolism

It is subject to limited metabolism (about 10%). Rosuvastatin is a non-core substrate for metabolism by cytochrome P450 isoenzymes.

The main isoenzyme involved in metabolism of rosuvastatin is CYP2C9. CYP2C19, CYP3A4 and CYP2D6 isoenzymes are less involved in metabolism.

The main identified metabolites of rosuvastatin are N-desmethylrosuvastatin and lactone metabolites. N-desmethylrosuvastatin is about 50% less active than rosuvastatin, lactone metabolites are pharmacologically inactive. More than 90% of the pharmacological activity for inhibition of circulating HMG-CoA reductase is provided by rosuvastatin, the rest by its metabolites.

Elimation

About 90% of the dose of rosuvastatin is excreted unchanged through the intestine (including absorbed and unabsorbed rosuvastatin). The remainder is excreted by the kidneys. Plasma elimination half-life (T1/2) is approximately 19 hours. The elimination half-life does not change with increasing drug dose. Mean geometric plasma clearance is approximately 50 L/hour (coefficient of variation 21.7%).

As with other HMG-CoA reductase inhibitors, the membrane cholesterol transporter is involved in the “hepatic” uptake of rosuvastatin and has an important role in hepatic elimination of rosuvastatin.

Linearity

The systemic exposure of rosuvastatin increases in proportion to the dose. Pharmacokinetic parameters do not change with daily administration.

Particular patient populations. Age and sex

Pass and age have no clinically significant effect on the pharmacokinetics of rosuvastatin.

Ethnic groups

. Pharmacokinetic studies have shown an approximately two-fold increase in the median area under the pharmacokinetic concentration-time curve (AUC) and maximum plasma concentration (Stach) of rosuvastatin in patients of the Mongoloid race (Japanese, Chinese, Filipino, Vietnamese, and Korean) compared with Caucasians; Hindus showed a 1.3-fold increase in median AUC and Cmax.

Pharmacokinetic analysis showed no clinically significant differences in pharmacokinetics among Caucasoid and non-Hispanic races.

Renal failure

In patients with mild to moderately severe renal failure the plasma concentration of rosuvastatin or N-desmethylrosuvastatin does not change significantly. In patients with severe renal insufficiency (creatinine clearance (CK) less than 30 ml/min) the plasma concentration of rosuvastatin is 3 times higher, and N-desmethylrosuvastatin concentration is 9 times higher than in healthy volunteers. Plasma concentrations of rosuvastatin were approximately 50% higher in patients on hemodialysis than in healthy volunteers.

Hepatic failure

In patients with various stages of hepatic failure no increase in the elimination half-life of rosuvastatin was found (in patients with a Child-Pugh score of 7 or lower). Two patients with Child-Pugh scores 8 and 9 showed at least 2-fold increase in half-life. There is no experience with rosuvastatin in patients with more than a Child-Pugh score of 9.

Genetic polymorphism

. HMG-CoA reductase inhibitors, including rosuvastatin, bind to the transport proteins OATP1B1 (organic anion transport polypeptide involved in statin uptake by hepatocytes) and BCRP (efflux transporter). Carriers of SLC01B1 (OATP1B1) C.521CC and ABCG2 (BCRP) C.421AAA genotypes had 1.6 and 2.4-fold increased exposure (AUC) to rosuvastatin, respectively, compared with carriers of SLC01B1 C.521TT ABCG2 C.421CC genotypes.

Indications

Active ingredient

Composition

Active substance:

Rosuvastatin calcium 41.60 mg (in conversion to rosuvastatin 40 mg).

Auxiliary substances:

Microcrystalline cellulose 77.08 mg,

Lactose monohydrate 157.32 mg,

Crospovidone 15.00 mg,

Meglumine 6.00 mg,

Magnesium stearate 3.00 mg;

Film sheath:

. Opadray II pink 32K540017 (lactose monohydrate 40.0%, hypromellose 15 cP 28.0%, titanium dioxide (E171) 22.22%), triacetin 8.0%, dye red charming (E129) 0.9%, dye sunset yellow (E110) 0.8%, dye indigo carmin (E132) 0.08%) 10.50 mg

How to take, the dosage

Ingestion. Any time of the day, regardless of meals.

The tablet should not be chewed or crushed and should be swallowed whole with water.

The patient should start on a standard hypocholesterolemic diet before therapy and continue during the entire period of treatment.

The dose of the drug should be adjusted individually depending on the goals of therapy and the therapeutic response to treatment, taking into account current accepted recommendations for target lipid concentrations.

The recommended starting dose for patients starting rosuvastatin or for patients transferred from other HMG-CoA reductase inhibitors should be 5 or 10 mg of the drug once daily. When choosing the initial dose, the individual cholesterol content should be guided and the possible risk of cardiovascular complications should be taken into account, as well as the potential risk of side effects should be assessed. If necessary, the dose may be increased in 4 weeks (see section “Pharmacodynamics”).

With regard to the possible development of side effects when taking a dose of 40 mg compared to lower doses of the drug (see section “Side Effects”). Due to the possible development of side effects of 40 mg compared to lower doses of the drug (see “Side Effects”), increasing the dose to 40 mg, after an additional dose above the recommended initial dose for 4 weeks of therapy, may only be undertaken in patients with severe hypercholesterolemia and with a high risk of cardiovascular complications (especially in patients with familial hypercholesterolemia), in whom the desired result of therapy was not achieved at the 20 mg dose and will be under medical supervision (see “Special Considerations”). We recommend especially close monitoring of patients receiving 40 mg.

Prescribing a dose of 40 mg to patients who have not previously seen a physician is not recommended. After 2-4 weeks of therapy and/or when increasing the dose of the drug, lipid metabolism parameters should be monitored, and the dose should be adjusted if necessary.

Elderly patients

Dose adjustment is not required.

Patients with renal impairment

Dose adjustment is not necessary in patients with mild to moderate renal impairment. In patients with severe renal failure (CKD less than 30 ml/min) the drug is contraindicated. The drug administration in dose 40 mg is contraindicated in patients with moderate renal impairment with CKD 30-60 ml/min (see section “Special indications” and “Pharmacodynamics”). In patients with moderate renal dysfunction, a starting dose of 5 mg is recommended.

Patients with hepatic impairment

The drug is contraindicated in patients with active liver disease (see section “Contraindications”).

Special populations. Ethnic groups

When studying pharmacokinetic parameters of rosuvastatin in patients belonging to different ethnic groups, an increased systemic concentration of rosuvastatin was noted among Japanese and Chinese (see section “Special indications”).

This fact should be considered when prescribing the drug in this group of patients. When prescribing doses of 10 mg and 20 mg, the recommended starting dose of the drug for mongoloid patients is 5 mg. A dose of 40 mg is contraindicated in patients of mongoloid race (see Contraindications).

Genetic polymorphisms

Carriers of the SLCOIBI (OATP1B1) C.521CC and ABCG2 (BCRP) C.421AA there was an increased exposure (AUC) to rosuvastatin compared with SLCOIBI C.521T ABCG2 C.421CC genotype carriers. For C.521CC or C.421AA genotype carriers the recommended maximum dose of rosuvastatin is 20 mg once daily (see sections “Pharmacokinetics”, “Special Considerations” and “Interaction with Other Medicinal Products and Other Drug Interactions”).

Patients with predisposition to myopathy

The drug is contraindicated at a dose of 40 mg in patients with factors that may indicate a predisposition to myopathy (see Contraindications). When doses of 10 mg and 20 mg are prescribed, the recommended starting dose for this group of patients is 5 mg (see Contraindications).

Companion therapy

Rosuvastatin binds to various transport proteins (in particular to OATP1B1 and BCRP). When co-administering rosuvastatin with drugs (such as cyclosporine, some HIV protease inhibitors, including the combination of ritonavir with atazanavir, lopinavir and/or tipranavir) that increase the plasma concentration of rosuvastatin through interaction with transport proteins, the risk of myopathy including rhabdomyolysis may increase (see sections “Cautions” and “Interaction with other medicinal products and other drug interactions”).

The instructions for use of these drugs should be read before prescribing them together with rosuvastatin. In such cases, the possibility of prescribing alternative therapy or temporary discontinuation of rosuvastatin should be assessed. If co-administration is necessary, the benefit-risk ratio of concomitant therapy with rosuvastatin should be assessed and the possibility of reducing its dose should be considered (see section “Interaction with other medicinal products and other drug interactions”).

Interaction

Influence of other drugs on rosuvastatin

Inhibitors of transport proteins

Rosuvastatin binds to several transport proteins, in particular to OATP1B1 and BCRP. Concomitant use of drugs that are inhibitors of these transport proteins may be accompanied by increased plasma concentrations of rosuvastatin and an increased risk of myopathy.

Cyclosporine

The concomitant use of rosuvastatin and cyclosporine increased AUC of rosuvastatin 7-fold compared to values obtained in healthy volunteers (see section “Contraindications”). Concomitant use of the drugs has no effect on the plasma concentration of cyclosporine.

Human immunodeficiency virus (HIV)protease inhibitors

While the exact mechanism of interaction is unknown, co-administration of rosuvastatin with HIV protease inhibitors may result in a significant increase in rosuvastatin exposure. In pharmacokinetic study, concomitant administration of 20 mg of rosuvastatin and combined preparation containing two HIV protease inhibitors (400 mg lopinavir / 100 mg ritonavir) in healthy volunteers showed 2-fold increase in AUQo-24) and 5-fold increase in Stakh rosuvastatin. Therefore, concomitant administration of rosuvastatin and HIV protease inhibitors in the treatment of patients with HIV is not recommended.

Gemfibrozil and other hypolipidemic agents

The concomitant use of rosuvastatin and gemfibrozil leads to a 2-fold increase in Cmax and AUC of rosuvastatin (see section “Special Precautions”). Based on the data of the study of specific interactions, no pharmacokinetic interaction with fenofibrate is expected, but pharmacodynamic interaction is possible. Hemfibrozil, fenofibrate, other fibrates and nicotinic acid at lipid-lowering doses (1 g or more per day) when used simultaneously with HMG-CoA reductase inhibitors increased the risk of myopathy, possibly due to the fact that they can also cause myopathy when used as monotherapy. Simultaneous use of 40 mg of rosuvastatin and fibrates is contraindicated (see section “Special Precautions” and “Contraindications”). When concomitant use of the drug with gemfibrozil and other hypolipidemic agents in dose more than 1 g/day the initial dose of the drug containing rosuvastatin should not exceed 5 mg.

Ezetimibe

The concomitant use of rosuvastatin at a dose of 10 mg and ezetimibe at a dose of 10 mg is observed to increase AUC of rosuvastatin in patients with hypercholesterolemia. An increased risk of side effects due to this pharmacodynamic interaction cannot be excluded.

Antacids

Concomitant use of rosuvastatin and suspensions of antacids containing aluminum or magnesium hydroxide may lead to a decrease in plasma concentration of rosuvastatin by approximately 50%. This effect is weaker if antacids are used 2 h after taking rosuvastatin. The clinical significance of this interaction has not been studied.

Eritromycin

Concomitant administration of rosuvastatin and erythromycin decreases AUC of rosuvastatin by 20% and TAC of rosuvastatin by 30%. This interaction may be due to increased intestinal motility caused by taking erythromycin.

Cytochrome P450 isoenzymes

The results of in vitro and in vivo studies have shown that rosuvastatin is neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. In addition, rosuvastatin is a rather weak substrate for these enzymes. Therefore, no interaction of rosuvastatin with other drugs at the level of metabolism involving cytochrome P450 isoenzymes is expected. No clinically significant interaction between rosuvastatin and fluconazole (inhibitor of CYP2C9 and CYP3A4 isoenzymes) and ketoconazole (inhibitor of CYP2A6 and CYP3A4 isoenzymes) was found.

Fusidic acid

There have been no studies. As with other statins, there have been post-marketing reports of cases of rhabdomyolysis when rosuvastatin and fusidic acid are taken together. Such patients should be closely monitored. If necessary, temporary discontinuation of rosuvastatin is possible.

Drug interactions that require dose adjustment of rosuvastatin

The dose of rosuvastatin should be adjusted if the instructions for use of the drug indicate an effect on rosuvastatin exposure. If exposure is expected to increase 2-fold or more, the starting dose of the drug should be 5 mg once daily. The maximum daily dose of rosuvastatin should also be adjusted so that the expected exposure to rosuvastatin does not exceed that for a dose of 40 mg taken without concomitant administration of drugs that interact with rosuvastatin. For example, maximum daily dose of the drug in concomitant use with gemfibrozil is 20 mg (1.9-fold increase in exposure), with ritonavir/atazanavir – 10 mg (3.1-fold increase in exposure).

The effect of concomitant therapy on the AUC of rosuvastatin (results of published clinical studies).

Companion therapy regimen

Rosuvastatin regimen

Change in AUC of rosuvastatin

Cyclosporine 75-200 mg 2 times daily, 6 months

/p>

10 mg once daily, 10 days

7.1-fold increase

10 mg once

Increased 3.1-fold

Simeprevir 150 mg once daily, 7 days

10 mg once

/p>

2.8-fold increase

Lopinavir 400 mg / ritonavir 100 mg, 2 times daily, 17 days

20 mg once daily, 7 days

2.1-fold increase

Clopidogrel 300 mg (loading dose) followed by 75 mg 24 hours later

20 mg once

2x increase

Hemfibrozil 600 mg 2 times daily, 7 days

80 mg once

1.9-fold increase

Eltrombopag 75 mg once daily, 10 days

10 mg once

1.6-fold increase

10 mg once daily, 7 days

Increased 1.5-fold

Tipranavir 500 g / ritonavir 200 mg, 2 times daily, 11 days

10 mg once

1.4-fold increase

Dronedarone 400 mg 2 times daily

No data

1.4-fold increase

Itraconazole 200 mg once daily, 5 days

10 or 80 mg once

1.4-fold increase

Ezetimibe 10 mg once daily, 14 days

10 mg once daily, 14 days

1.2-fold increase

Fosamprenavir 700 mg / ritonavir, 100 mg, 2 times daily, 8 days

10 mg once

No change

Aleglitazar 0.3 mg, 7 days

40 mg, 7 days

No change

Silymarin 140 mg 3 times daily, 5 days

10 mg once

No change

Phenofibrate 67 mg 3 times daily, 7 days

/td>

10 mg, 7 days

No change

Rifampin 450 mg once daily, 7 days

20 mg once

No change

Ketoconazole 200 mg 2 times daily, 7 days

80 mg once

No change

Fluconazole 200 mg once daily, 11 days

80 mg once

No change

/p>

Erythromycin 500 mg 4 times daily, 7 days

/p>

80 mg once

28% reduction

20 mg once

47% reduction

/td>

The effect of rosuvastatin use on other drugs

Special Instructions

Renal effects

In patients receiving high doses of rosuvastatin (mainly 40 mg), tubular proteinuria was observed, which in most cases was transient. Such proteinuria was not indicative of acute kidney disease or progression of renal disease. The incidence of serious renal dysfunction is increased when taking 40 mg of rosuvastatin. In patients taking the drug at a dose of 40 mg, it is recommended to monitor renal function parameters.

Motor system disorders

Myalgia, myopathy, and, rarely, rhabdomyolysis have been observed with rosuvastatin at all doses, and especially with doses above 20 mg.

Creatine phosphokinase (CPK)

The determination of CPK activity should not be performed after vigorous exercise or in the presence of other possible causes of increased CPK activity, which may lead to misinterpretation of results. If the baseline CPK level is significantly elevated (more than 5 times the upper limit of normal), the measurement should be repeated after 5-7 days. Therapy should not be started if the repeat measurement confirms the baseline CPK level (5 times higher than the upper limit of normal).

Before initiating therapy

When prescribing rosuvastatin, as well as other HMG-CoA reductase inhibitors, caution should be exercised in patients with existing risk factors for myopathy/rhabdomyolysis (see “Caution. section “Caution”), the risk/benefit ratio of therapy should be considered and clinical monitoring should be performed.

At the time of therapy

The patient should be informed of the need to promptly inform the physician if muscle pain, muscle weakness, or cramps occur unexpectedly, especially if combined with malaise or fever. In such patients, monitoring of CPK activity should always be performed. Treatment should be discontinued if CPK levels are more than 5 times the upper limit of normal or if muscle symptoms are severe and cause daily discomfort, even if CPK activity is not more than 5 times the upper limit of normal.

If symptoms disappear and CPK activity returns to normal, re-prescribing rosuvastatin or other HMG-CoA reductase inhibitors at lower doses with close monitoring of the patient should be considered. Routine monitoring of CPK activity in the absence of symptoms is unnecessary.

There have been very rare cases of immune-mediated necrotizing myopathy with clinical manifestations as persistent proximal muscle weakness and increased serum CPK activity during treatment or upon discontinuation of statins, including rosuvastatin. Additional muscular and nervous system studies, serological studies, and therapy with immunosuppressive agents may be required. No evidence of increased skeletal muscle effects with rosuvastatin and concomitant therapy has been noted.

Contraindications

For daily doses of 5 mg, 10 mg and 20 mg:

– hypersensitivity to rosuvastatin or any of the ingredients of the drug;

– Lactose intolerance, lactase deficiency or glucose-galactose malabsorption (because the drug contains lactose);

– Age less than 18 years (efficacy and safety not established);

– active liver disease, including a persistent increase in “hepatic” transaminase activity and any increase in “hepatic” transaminase activity in serum more than 3 times the upper limit of normal;

– severe renal dysfunction (CKG less than 30 ml/min);

– myopathy;

– concomitant administration of cyclosporine;

– in women: pregnancy, breastfeeding period, lack of reliable methods of contraception;

– patients predisposed to the development of myotoxic complications.

For a daily dose of 40 mg:

– hypersensitivity to rosuvastatin or any of the components of the drug;

– active hepatic disease, including a persistent increase in hepatic transaminase activity and any increase in serum hepatic transaminase activity greater than 3 times the upper limit of normal;

– presence of risk factors for myopathy/rhabdomyolysis (moderate renal failure (CKD less than 60 ml/min), hypothyroidism, myopathy in anamnesis (including hereditary forms), myotoxicity with a history of taking other HMG-CoA reductase inhibitors or fibrates, excessive alcohol intake, conditions that may lead to increased plasma concentrations of rosuvastatin, concomitant use of fibrates, use in patients of mongoloid race);

– concomitant use of cyclosporine;

– in women: pregnancy, breastfeeding period, lack of reliable methods of contraception;

– use in patients predisposed to the development of myotoxic complications;

– Lactose intolerance, lactase deficiency or glucose-galactose malabsorption (the drug contains lactose);

– Under 18 years of age (efficacy and safety not established);

With caution

For a daily dose of 5 mg. 10 mg and 20 mg

Risk for myopathy/rhabdomyolysis – renal failure, hypothyroidism; personal or family history of hereditary muscle disease and prior history of muscle toxicity with other HMG-CoA reductase inhibitors (statins) or fibrates; excessive use of alcohol; conditions with increased plasma concentrations of rosuvastatin; age over 65 years; history of liver disease; sepsis; arterial hypotension; major surgical interventions; trauma; severe metabolic, endocrine or electrolyte disorders; uncontrolled seizures; race (mongoloid race); concomitant use of fibrates.

For a daily dose of 40 mg

Having a risk of myopathy/rhabdomyolysis – mild renal failure (CK more than 60 ml/min); age over 65 years; history of liver disease; sepsis; arterial hypotension; major surgical interventions; trauma; severe metabolic, endocrine, or electrolyte disorders; uncontrolled epilepsy.

Pediatric use

The efficacy and safety of the drug in children under 18 years of age has not been established. The experience of using the drug in pediatric practice is limited to a small number of children (8 years and older) with familial homozygous hypercholesterolemia. Currently, it is not recommended to use rosuvastatin in children under 18 years of age.

Side effects

The side effects observed with rosuvastatin are usually mild and go away on their own. As with the use of other HMG-CoA reductase inhibitors, the incidence of side effects is mainly dose-dependent,

The incidence of adverse effects is as follows: Frequent (1/10 to 1/100 appointments); infrequent (1/100 to 1/1000 appointments); rare (1/1000 to 1/10,000 appointments), very rare (< 1/10,000); frequency unknown (cannot be calculated from available data).

Disorders of the blood and lymphatic system

Rarely, thrombocytopenia.

Nervous system disorders

Often – headache, dizziness; very rare – peripheral neuropathy, loss or reduction of memory; frequency unknown – sleep disturbance, including insomnia and “nightmares” dreams.

Mental disorders

Prevalence unknown – depression.

Disorders of the digestive system

Often – constipation, nausea, abdominal pain; infrequently – vomiting; rarely – pancreatitis; frequency unknown – diarrhea.

Hepatic and biliary tract disorders

Rarely – transient increase in “hepatic” transaminase activity in a small number of patients; very rare – hepatitis, jaundice.

Respiratory system disorders

Infrequent unknown – cough, shortness of breath.

Disorders of the immune system

Rarely – hypersensitivity reactions, including angioedema. Endocrine system disorders Often – type 2 diabetes mellitus.

Musculoskeletal and connective tissue disorders

Often – myalgia; rarely – myopathy (including myositis), rhabdomyolysis (in patients treated with doses of > 20 mg per day); very rare – arthralgia, tendopathies, possibly with tendon rupture; frequency unknown – immune-mediated necrotizing myopathy.

Skin and subcutaneous tissue disorders

Infrequent – skin itching, skin rash, urticaria; frequency unknown – Stephen-Johnson syndrome.

Recreational and urinary tract disorders

Often – proteinuria (with an incidence greater than 3% in patients receiving a dose of 40 mg), decreasing with therapy and not associated with the occurrence of renal disease, urinary tract infection; very rare – hematuria.

Gender and breast disorders

Very rare – gynecomastia.

Influence on the indicators of laboratory and instrumental studies

Infrequent – transient dose-dependent increase in serum creatine phosphokinase-CFC activity (if increased by more than 5 times the upper limit of normal, therapy should be temporarily suspended), increased plasma concentration of glycosylated hemoglobin; frequency unknown – thyroid function abnormality, increased concentration of glucose, bilirubin, alkaline phosphatase activity, gamma-glutamyl transpeptidase.

Others

Often – asthenia; frequency unknown – peripheral edema.

Some statins

The following side effects have been reported with some statins: erectile dysfunction; isolated cases of interstitial lung disease, especially with long-term use; type 2 diabetes: frequency depends on the presence or absence of risk factors (fasting blood glucose concentration 5.6 – 6.9 mmol/l, body mass index (BMI) >30 kg/m2, hypertriglyceridemia, arterial hypertension in the history.

Overdose

Similarities